Tokyo Tape
Sign in
← OncoTherapy Science

Quarterly report · Q2

4564.TEDINET S100S8MF
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥356m2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥515m2022-04-01 → 2022-09-30Cons.Net sales
Operating income−¥695m2023-04-01 → 2023-09-30Cons.Operating income
Operating income−¥618m2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income−¥708m2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income−¥1.1bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥644m2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax−¥709m2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax−¥613m2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)−¥711m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.1bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥614m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income−¥711m2023-04-01 → 2023-09-30Cons.Profit loss
Net income−¥614m2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥1.2bnat 2023-09-30Cons.Assets
Total assets¥1.5bnat 2023-03-31Cons.Assets
Total assets¥1.7bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥233mat 2023-09-30Cons.Liabilities
Total liabilities¥656mat 2023-03-31Cons.Liabilities
Net assets / equity¥935mat 2023-09-30Cons.Net assets
Net assets / equity¥855mat 2023-03-31Cons.Net assets
Net assets / equity¥1.3bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥881mat 2023-09-30Cons.Cash and deposits
Cash and deposits¥1.1bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥881mat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.1bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥1.3bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥1.8bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow−¥880m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥795m2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥517m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥34m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥20m2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥7m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥677m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥96m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-3.422023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.452023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-5.812022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-3.192022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.742022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio73.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio51.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio76.3%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥149,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥149,000
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥183m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥356m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥356m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥109m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2023-04-01 → 2023-09-30¥537,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2023-04-01 → 2023-09-30¥387,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥149,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2023-04-01 → 2023-09-30−¥403m
—segment totalrevenue2023-04-01 → 2023-09-30¥357m
—segment totalrevenue external2023-04-01 → 2023-09-30¥356m
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥149,000
—segment totalsegment profit2023-04-01 → 2023-09-30−¥512m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥111,000
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥111,000
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥188m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥507m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥507m
jpcrp040300-q2r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥48m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2022-04-01 → 2022-09-30¥8m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2022-04-01 → 2022-09-30¥8m
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥111,000
jpcrp040300-q2r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2022-04-01 → 2022-09-30−¥382m
—segment totalrevenue2022-04-01 → 2022-09-30¥515m
—segment totalrevenue external2022-04-01 → 2022-09-30¥515m
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥111,000
—segment totalsegment profit2022-04-01 → 2022-09-30−¥430m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 421
ItemContextValueUnit
Other caPrior1YearInstant65755000JPY
Other caCurrentQuarterInstant71249000JPY
Current assetsPrior1YearInstant1422260000JPY
Current assetsCurrentQuarterInstant1118012000JPY
BuildingsPrior1YearInstant254674000JPY
BuildingsCurrentQuarterInstant254674000JPY
Accumulated depreciation and impairment loss buildingsPrior1YearInstant-254674000JPY
Accumulated depreciation and impairment loss buildingsCurrentQuarterInstant-254674000JPY
Buildings netPrior1YearInstant－JPY
Buildings netCurrentQuarterInstant－JPY
Machinery and equipmentPrior1YearInstant3971000JPY
Machinery and equipmentCurrentQuarterInstant3165000JPY
Accumulated depreciation and impairment loss machinery and equipmentPrior1YearInstant-3971000JPY
Accumulated depreciation and impairment loss machinery and equipmentCurrentQuarterInstant-3165000JPY
Machinery and equipment netPrior1YearInstant－JPY
Machinery and equipment netCurrentQuarterInstant－JPY
Tools furniture and fixturesPrior1YearInstant963896000JPY
Tools furniture and fixturesCurrentQuarterInstant963391000JPY
Accumulated depreciation and impairment loss tools furniture and fixturesPrior1YearInstant-963896000JPY
Accumulated depreciation and impairment loss tools furniture and fixturesCurrentQuarterInstant-963391000JPY
Tools furniture and fixtures netPrior1YearInstant－JPY
Tools furniture and fixtures netCurrentQuarterInstant－JPY
Property plant and equipmentPrior1YearInstant－JPY
Property plant and equipmentCurrentQuarterInstant－JPY
Guarantee deposits ioaPrior1YearInstant89178000JPY
Guarantee deposits ioaCurrentQuarterInstant49721000JPY
Investments and other assetsPrior1YearInstant89178000JPY
Investments and other assetsCurrentQuarterInstant49721000JPY
Noncurrent assetsPrior1YearInstant89178000JPY
Noncurrent assetsCurrentQuarterInstant49721000JPY
AssetsPrior1YearInstant1511438000JPY
AssetsCurrentQuarterInstant1167733000JPY
Accounts payable otherPrior1YearInstant248799000JPY
Accounts payable otherCurrentQuarterInstant94593000JPY
Contract liabilitiesPrior1YearInstant146208000JPY
Contract liabilitiesCurrentQuarterInstant－JPY
Income taxes payablePrior1YearInstant69380000JPY
Income taxes payableCurrentQuarterInstant70115000JPY
Other clPrior1YearInstant144835000JPY
Other clCurrentQuarterInstant20924000JPY
Current liabilitiesPrior1YearInstant609224000JPY
Current liabilitiesCurrentQuarterInstant185632000JPY
Asset retirement obligations nclPrior1YearInstant47045000JPY
Asset retirement obligations nclCurrentQuarterInstant47105000JPY
Noncurrent liabilitiesPrior1YearInstant47045000JPY
Noncurrent liabilitiesCurrentQuarterInstant47105000JPY
LiabilitiesPrior1YearInstant656269000JPY
LiabilitiesCurrentQuarterInstant232738000JPY
Capital stockPrior1YearInstant789114000JPY
Capital stockCurrentQuarterInstant1183814000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass